Avita Medical (RCEL) Expected to Post Earnings on Thursday

Avita Medical (NASDAQ:RCEL) is expected to be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.2928) per share and revenue of $20.25 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Avita Medical (NASDAQ:RCEL) last released its earnings results on Thursday, May 14th. The company reported ($0.35) earnings per share for the quarter, meeting the consensus estimate of ($0.35). The company had revenue of $19.25 million for the quarter, compared to the consensus estimate of $18.30 million. On average, analysts expect Avita Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Avita Medical Stock Performance

NASDAQ:RCEL opened at $4.44 on Thursday. The stock’s fifty day moving average is $4.39 and its 200 day moving average is $4.35. Avita Medical has a fifty-two week low of $3.22 and a fifty-two week high of $7.12. The firm has a market capitalization of $136.66 million, a PE ratio of -2.83 and a beta of 1.86.

Analysts Set New Price Targets

Several research firms have commented on RCEL. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Avita Medical in a research note on Wednesday, June 24th. D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Avita Medical in a research note on Wednesday, April 8th. TD Cowen restated a “buy” rating on shares of Avita Medical in a report on Tuesday, June 30th. Lake Street Capital raised shares of Avita Medical from a “hold” rating to a “buy” rating and lifted their price target for the stock from $3.50 to $6.00 in a research note on Friday, May 15th. Finally, Wall Street Zen downgraded shares of Avita Medical from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $7.25.

Insider Buying and Selling at Avita Medical

In other Avita Medical news, Director Joseph Fralin Woody acquired 10,000 shares of the company’s stock in a transaction dated Tuesday, June 9th. The shares were purchased at an average cost of $4.19 per share, for a total transaction of $41,900.00. Following the completion of the purchase, the director owned 102,761 shares in the company, valued at approximately $430,568.59. This trade represents a 10.78% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last three months, insiders have purchased 37,200 shares of company stock valued at $155,080. 2.24% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Avita Medical

A number of large investors have recently bought and sold shares of RCEL. Deutsche Bank AG lifted its holdings in Avita Medical by 1,351.5% during the fourth quarter. Deutsche Bank AG now owns 7,896 shares of the company’s stock worth $27,000 after buying an additional 7,352 shares during the period. Russell Investments Group Ltd. boosted its position in Avita Medical by 122.2% during the 4th quarter. Russell Investments Group Ltd. now owns 8,047 shares of the company’s stock valued at $28,000 after acquiring an additional 4,425 shares in the last quarter. Aristides Capital LLC purchased a new position in shares of Avita Medical in the 4th quarter valued at $48,000. The Manufacturers Life Insurance Company purchased a new position in shares of Avita Medical in the 2nd quarter valued at $58,000. Finally, Wells Fargo & Company MN raised its position in shares of Avita Medical by 98.5% in the 4th quarter. Wells Fargo & Company MN now owns 18,832 shares of the company’s stock worth $65,000 after acquiring an additional 9,345 shares in the last quarter. Institutional investors own 27.66% of the company’s stock.

Avita Medical Company Profile

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.

Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S.